Junichi Seike

Sentinel Lymph Node Biopsy Using Intraoperative Indocyanine Green Fluorescence Imaging Navigated with Preoperative CT Lymphography for Superficial Esophageal Cancer

BackgroundThe sentinel lymph node (SLN) concept has been gaining attention for gastrointestinal neoplasms but remains controversial for esophageal cancer. This study evaluated the feasibility of SLN identification using intraoperative indocyanine green (ICG) fluorescence imaging (IGFI) navigated by preoperative computed tomographic lymphography (CTLG) to treat superficial esophageal cancer.MethodsSubjects comprised 20 patients clinically diagnosed with superficial esophageal cancer. Five minutes after endoscopic submucosal injection of iopamidol around the primary lesion using a four-quadrant injection pattern with a 23-gauge endoscopic injection sclerotherapy needle, three-dimensional multidetector computed tomography was performed to identify SLNs and lymphatic routes. ICG solution was injected intraoperatively around the tumor. Fluorescence imaging was obtained by infrared ray electronic endoscopy. Thoracoscope-assisted standard radical esophagectomy with lymphadenectomy was performed to confirm fluorescent lymph nodes detected by CTLG.ResultsLymphatic vessels and SLNs were identified preoperatively using CTLG in all cases. Intraoperative detection rates were 100% using CTLG and 95% using IGFI. Lymph node metastases were found in four cases, including one false-negative case with SLNs occupied by bulky metastatic tumor that were not enhanced with both methods. The other 19 cases, including three cases of metastatic lymph nodes, were accurately identified by both procedures.ConclusionsPreoperative CTLG visualized the correct number and site of SLNs in surrounding anatomy during routine computed tomography to evaluate distant metastases. Referring to CTLG, SLNs were identified using IGFI, resulting in successful SLN navigation and saving time and cost. This method appears clinically applicable as a less-invasive method for treating superficial esophageal cancer.

A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Purpose. Docetaxel/5-FU/CDDP (DFP) therapy is a useful treatment for advanced esophageal cancer. However, adverse reactions such as chemotherapy-induced nausea and vomiting (CINV) interfere often with continuation of the chemotherapy. We investigated the efficacy of rikkunshito (TJ-43) on CINV. Methods. Nineteen patients who were going to undergo DFP therapy were enrolled. They were assigned to the following two groups: a TJ-43-treated group and -nontreated group. The following parameters were compared between the 2 groups: (1) the frequency of symptoms occurred, (2) vomiting, nausea, and anorexia score, and (3) QOL score. Results. The incidence of symptoms was lower in the TJ-43-treated group than that in the control group. The nausea score of the TJ-43-treated group was significantly lower than that of the control group. In the QOL score, the mood score and the ADL score decreased significantly in the control group. Conclusion. We recommend TJ-43 administration in patients undergoing DFP chemotherapy.

Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus

BackgroundDocetaxel is a powerful anticancer agent for esophageal cancer. Preoperative combined chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil (DFP) followed by surgery is expected to improve the survival of patients with resectable esophageal squamous cell carcinoma.MethodsClinical stage II/III squamous cell carcinoma patients who received DFP followed by esophagectomy (NAC group, n = 13) were compared retrospectively with patients who received surgery without preoperative DFP (Surgery group, n = 12). Not only the efficacy and toxicity of initial chemotherapy but also morbidity and survival after esophagectomy were assessed.ResultsOf 13 patients, the overall response rate was 92.3%; 30.8% (4/13) patients had CR, 61.5% (8/13) PR, 7.7% (1/13) SD, and 0 (0/13) PD. The 4 patients who achieved a pathological complete response (pCR) included 1 with cT4N1M0, 2 with cT3N1M0, and 1 with cT3N0M0. More than grade 3 toxicity of neutropenia and stomatitis occurred in 15.4% and 23.1% of patients, respectively. Leakage was 23.1% in the NAC group and 8.3% in the Surgery group. No treatment-related deaths occurred in the NAC group.ConclusionsThis regimen as preoperative chemotherapy seemed to provide a high response rate and a favorable survival benefit with acceptable toxicity and morbidity. To validate the clinical significance of this protocol, a randomized trial is essential.

Esofagectomia Transiatale Con Assistenza Videomediastinoscopica

L’esofagectomia transtoracica (addominotoracica) “en bloc” (TTE) con dissezione linfonodale a tre livelli ha migliorato la sopravvivenza dei pazienti affetti da cancro esofageo [1,2].